Business Wire

Western Union Supports Displaced People of the Moria Camp

Share

Western Union, a global leader in cross-border, cross-currency money movement and payments, and the Western Union Foundation have announced the Foundation’s pledge of USD 250K in relief to support the immediate and long term recovery needs of refugees including the people displaced from Greece’s Moria Camp. More than 12,000 people have been evacuated from the Moria Camp on the island of Lesbos, which was destroyed by fires earlier this week.

The camp was the temporary home to migrants, refugees and asylum seekers from more than 70 different countries, among them elderly, pregnant women, children, and people with disabilities. With a fire devastating their only place of refuge, thousands are now without shelter and access to water and sanitation.

The Foundation will deploy USD 100K to support the International Rescue Committee (IRC) in their immediate relief efforts for the Moria camp evacuees. Funds will support secure accommodations, mental health and psychosocial support, and distribution of urgent supplies, with a focus on safety to avoid the risk of COVID-19 transmission. An additional USD 150K in funding will support longer-term advocacy and relief efforts to enable sustainable living for refugees in Greece.

“Western Union and our Foundation are unrelenting in our support of migrants, refugees and forcibly displaced people around the globe. Our hearts are with the people of the Moria camp,” said Hikmet Ersek, Western Union President and CEO. “Many of our customers are migrants who have moved from their home to their host country for a variety of reasons - economic, financial, family-driven, or security reasons.”

“We call on global leaders to come together to support this vulnerable community as their survival is at stake. We know first-hand that people thrive when they are given fundamental support and opportunities through education, job skills training, and access to the global economy.”

In a recent statement released by the IRC, Dimitra Kalogeropoulou, IRC Greece Country Director, said, “The recent events in Moria are unthinkable but, tragically, predictable. The dire situation on the islands has gone on for far too long. With the camp destroyed and residents evacuated, the situation is alarming as there is no secure place to live. These already traumatized people have now lost what few belongings they had; they have nothing.”

Since its inception, the Western Union Foundation has granted USD 10.5M globally to support displaced persons, including immigrants, refugees, asylees, conflict-affected, and migrants. This includes USD 2.5M across Europe.

Since 2018, the Western Union Foundation, in partnership with MIT D-Lab, has been providing hands-on, experiential learning in design, innovation, and entrepreneurship for refugees in Greece. These individuals are being equipped with technical and soft skills to establish their own business while building confidence, agency, and problem-solving ability.

Globally, more than 70 million people were forced from home by conflict and persecution at the end of 2018, according to the UN. Among them are nearly 30 million refugees, over half of whom are under the age of 18. There are also millions of stateless people who have been denied a nationality and access to fundamental rights such as education, healthcare, employment, and freedom of movement.

WU-G

About Western Union

The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement and payments. Our omnichannel platform connects the digital and physical worlds and makes it possible for consumers and businesses to send and receive money and make payments with speed, ease, and reliability. As of June 30, 2020, our network included over 550,000 retail agent locations offering our branded services in more than 200 countries and territories, with the capability to send money to billions of accounts. Additionally, westernunion.com, our fastest growing channel in 2019, is available in over 75 countries, plus additional territories, to move money around the world. With our global reach, Western Union moves money for better, connecting family, friends, and businesses to enable financial inclusion and support economic growth. For more information, visit www.westernunion.com.

About the Western Union Foundation

The Western Union Foundation believes that education is the surest pathway to economic opportunity. After nearly 20 years of impact, we are continuing to deliver against our mission with our Opportunity Beyond Borders commitment, with a focus on empowering forcibly displaced and marginalized youth with the training and education needed to succeed in today’s technology-driven global economy. The Foundation also provides funding to communities in crisis through disaster relief and other humanitarian efforts, a key reason for forced migration. To date, more than $126 million granted to fund projects and scholarships in 174 countries across the globe. The Western Union Foundation is a separate charitable corporation that is tax-exempt under 501(c)(3) of the US Internal Revenue Code and receives support from The Western Union Company, its employees, agents, and business partners. Contributions to the Foundation are tax-deductible for US income tax purposes. To learn more, visit wu.com/foundation or follow us on Twitter @TheWUFoundation.

Contact information

Western Union Global Communications; Pia De Lima; Pia.DeLima@westernunion.com

Western Union Americas: Margaret Fogarty; margaret.fogarty@wu.com

Western Union Middle East & Africa: Mohamed El Khalouki; Mohamed.ElKhalouki@wu.com

Western Union Asia-Pacific: Karen Santos; Karen.Santos2@westernunion.com

Western Union Foundation: Emily Larson; emily.larson@wu.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Janssen Presents Findings from Global, Multi-Centre Trial Examining Amivantamab in Combination with Lazertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer21.9.2020 01:01:00 CESTPress release

FOR EU TRADE AND MEDICAL MEDIA ONLY. NOT FOR DISTRIBUTION IN BENELUX. The Janssen Pharmaceutical Companies of Johnson & Johnson announced yesterday interim results from the CHRYSALIS study (NCT02609776) evaluating amivantamab, a fully human bispecific antibody that targets epidermal growth factor receptor (EGFR) and mesenchymal epithelial transition factor (MET) mutations,1 in combination with the third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib2 in patients with non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or L858R mutations.3 Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1), clinical benefit rate, duration of response and the safety profile of amivantamab and lazertinib,in the 91 patients treated with the combination across dose escalation and expansion cohorts.3 The study results were presented at the European Society for Medical Oncology (ESMO) Virtual Cong

ESMO 2020: Cabometyx ® (cabozantinib) in Combination With Opdivo ® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 18:30:00 CESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 12:55:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 12:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 09:30:00 CESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 08:00:00 CESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price